June 27, 2025

Botulinum Toxin and Scopolamine for Radiation-Induced Salivary Gland Toxicity in Metastatic Prostate Cancer

Injection with botulinum toxin type A plus transdermal scopolamine led to the reduction in radiation-induced salivary gland toxicity without compromising PSMA tumor uptake in patients with metastatic ...

The ASCO Post

June 27, 2025

Best Practice Recommendations for Clinical Homologous Recombination Deficiency Testing

The Association for Molecular Pathology has introduced best practice recommendations for clinical laboratories developing and performing homologous recombination deficiency testing.

The ASCO Post

June 27, 2025

Combination Therapy for Newly Diagnosed, BRCA-Nonmutated, Advanced Epithelial Ovarian Cancer

The outcomes from the phase III ENGOT-OV43/GOG-3036/KEYLYNK-001 trial in advanced BRCA-nonmutated ovarian cancer indicate a statistically significant and clinically meaningful benefit for the PD-1 inh...

The ASCO Post

June 27, 2025

Predictive Biomarker Under Study in Colorectal Cancer

Researchers have uncovered a biomarker that may determine response to cell therapy and survival in patients with colorectal cancer.

The ASCO Post

June 26, 2025

GPC3-Targeted ImmunoPET Helps Detect Earlier-Stage Hepatocellular Carcinoma

A novel immunoPET imaging agent targeting GPC3 demonstrated high sensitivity and specificity in detecting GPC3-positive hepatocellular carcinoma (HCC) tumors, according to the results of a pilot clini...

The ASCO Post

June 25, 2025

Number of Cancer Survivors in the United States Reaches 18.6 Million and Projected to Exceed 22 Million by 2035

The number of people living with a history of cancer in the United States is estimated at 18.6 million as of January 1, 2025, and projected to exceed 22 million by 2035, according to a new report, Can...

The ASCO Post

June 19, 2025

Ropeginterferon Alfa-2b Outperforms Anagrelide as Second-Line Therapy for ET, Study Finds

Ropeginterferon alfa-2b demonstrated superior efficacy and safety compared with anagrelide as second-line therapy for patients with essential thrombocythemia (ET) who were intolerant or resistant to h...

The ASCO Post

June 18, 2025

NCCN Clinical Practice Guidelines in Oncology: 2025 Updates

The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are availa...

The ASCO Post

June 13, 2025

Relacorilant and Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

In a phase III trial (ROSELLA) reported in The Lancet, Olawaiye et al examined the survival benefit of adding relacorilant to nab-paclitaxel in women with platinum-resistant ovarian cancer. Relacorila...

The ASCO Post